Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 to 65 years who present to the GI clinic for an EGD or colonoscopy~Exclusion Criteria:~* Poor vital sign stability~* Hypoxia: O2 \< 92%,~* Hypotension, hypertension, heart rate and respiratory rates greater than 20% above or below normal as dictated by normal ranges in SAMMC protocol~* Any allergy to ketamine, fentanyl, or midazolam~* Patient is pregnant or refuses pregnancy test, in women of child-bearing potential.\*~* American Society of Anesthesiologists (ASA) score\>3~* Presence of a history of psychosis, hallucinations, and/or a psychotic disorder~* History of increased intracranial pressure/ hypertensive hydrocephalus within the last 3 months~* Active pulmonary infection or disease.~* History of airway instability, tracheal surgery, or tracheal stenosis.~  * \* Not applicable if patient is a female over 50 years old or has had a hysterectomy and/or oophorectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
- Control (Type: ACTIVE_COMPARATOR): This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).